Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELIVER
NCT03965923Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of dapivirine in human immunodeficiency virus infection (HIV) (6 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants With a Composite Safety Endpoint Adverse Event at Week 52 and Pregnancy Outcomes. Started Jan 2020; status: completed.
02
Drugs
dapivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03965923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03965923.